<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01159119</url>
  </required_header>
  <id_info>
    <org_study_id>PR-012</org_study_id>
    <nct_id>NCT01159119</nct_id>
  </id_info>
  <brief_title>A Study of EUR-1066 in Subjects With Chronic Pancreatitis, Exocrine Pancreatic Insufficiency and Chronic Abdominal Pain</brief_title>
  <acronym>EUR-1066</acronym>
  <official_title>Single Center Randomized Single Blind Crossover Group Active Control Study to Evaluate Safety and Efficacy of EUR-1066 a Pancreatic Enzyme Product in Patients With Chronic Pancreatitis Exocrine Pancratic Insufficiency,Chronic Abdominal Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Forest Laboratories</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Forest Laboratories</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate two different treatments in subjects with chronic
      pancreatitis, exocrine pancreatic insufficiency and chronic abdominal pain.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate two different preparations of a pancreatic enzyme in subjects with chronic
      pancreatitis, exocrine pancreatic insufficiency, and chronic abdominal pain.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date type="Actual">August 2, 2010</start_date>
  <completion_date type="Actual">July 1, 2011</completion_date>
  <primary_completion_date type="Actual">July 1, 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparing frequency and severity of pain</measure>
    <time_frame>up to 84 days</time_frame>
    <description>Patient diary</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in fat malabsorption</measure>
    <time_frame>up to 124 days</time_frame>
    <description>Assess the coefficient of fat absorption</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Chronic Pancreatitis</condition>
  <arm_group>
    <arm_group_label>EUR-1066-A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with Eur-1006-A.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EUR-1066-B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with Eur-1066-B</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Zenpep</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Control Group: Consist of treatment with Zenpep</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EUR-1066-A</intervention_name>
    <description>Eur-1066 capsules taken daily for 28 days either during treatment period 1 or treatment period 3.</description>
    <arm_group_label>EUR-1066-A</arm_group_label>
    <other_name>EUR-1066</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zenpep</intervention_name>
    <description>Capsules taken for daily for 28 days during treatment period 2</description>
    <arm_group_label>Zenpep</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EUR-1066-B</intervention_name>
    <description>Eur-1066 capsules taken daily for 28 days either during treatment period 1 or treatment period 3.</description>
    <arm_group_label>EUR-1066-B</arm_group_label>
    <other_name>EUR-1066</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of Chronic Pancreatitis

          -  Exocrine Pancreatic Insufficiency

          -  Chronic abdominal pain

        Exclusion Criteria:

          -  Acute pancreatitis

          -  Active alcohol consumption

          -  Uncontrolled diabetes
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Phillip Toskes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florida</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>July 5, 2010</study_first_submitted>
  <study_first_submitted_qc>July 7, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2010</study_first_posted>
  <last_update_submitted>January 13, 2020</last_update_submitted>
  <last_update_submitted_qc>January 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Abdominal Pain</keyword>
  <keyword>Exocrine Pancreatic Insufficiency</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatitis</mesh_term>
    <mesh_term>Pancreatitis, Chronic</mesh_term>
    <mesh_term>Exocrine Pancreatic Insufficiency</mesh_term>
    <mesh_term>Abdominal Pain</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

